Lineage Cell Therapeutics (LCTX) Income from Continuing Operations (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Income from Continuing Operations of 19329000.0 for Q1 2026, down 183.83% year-over-year from 23056663.16 in Q1 2025, and down 181.89% quarter-over-quarter from 6857000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 19329000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 183.83% year-over-year to 19329000.0; the TTM figure through Mar 2026 stood at 67568000.0 (down 258.76% YoY), while the FY2025 annual figure was 63367000.0, down 241.01% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19329000.0, down from 6857000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3001000.0 in Q3 2024, with the low at 22535000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 6558000.0 (2024), against an average of 8277058.82.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 77.43% in 2022, then plunged 528.02% in 2025.
- Lineage Cell Therapeutics' Income from Continuing Operations stood at 6321000.0 in 2022, then increased by 25.42% to 4714000.0 in 2023, then jumped by 31.06% to 3250000.0 in 2024, then slumped by 110.98% to 6857000.0 in 2025, then sank by 181.89% to 19329000.0 in 2026.
- Business Quant data shows LCTX's Income from Continuing Operations at 19329000.0 in Q1 2026, 6857000.0 in Q4 2025, and 18847000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -15.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.61 Mn |
| Mar 31, 2026 | -19.33 Mn |
| Dec 31, 2025 | -6.86 Mn |
| Sep 30, 2025 | -18.85 Mn |
| Jun 30, 2025 | -22.54 Mn |
| Mar 31, 2025 | -6.81 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -7.16 Mn |
| Jun 30, 2023 | -5.20 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -6.32 Mn |
| Sep 30, 2022 | -6.08 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.01 Mn |
| Sep 30, 2021 | -7.83 Mn |